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Abstract
Dendritic cells (DCs) play a key role in innate and adaptive immunity but the access to sufficient amount of DCs
for basic and translational research has been limited.
We established a novel ex vivo system to develop and expand DCs from hematopoietic stem/progenitor cells
(HPCs). Both human and mouse HPCs were expanded first in feeder culture supplemented with c-Kit ligand (KL,
stem cell factor, steel factor or CD117 ligand), Flt3 ligand (fms-like tyrosine kinase 3, Flt3L, FL), thrombopoietin
(TPO), IL-3, IL-6, and basic fibroblast growth factor (bFGF), and then in a second feeder culture ectopically expres-
sing all above growth factors plus GM-CSF and IL-15.
In the dual culture system, CD34
+ HPCs differentiated toward DC progenitors (DCPs), which expanded more than
five orders of magnitude. The DCPs showed myeloid DC surface phenotype with up-regulation of transcription fac-
tors PU.1 and Id2, and DC-related factors homeostatic chemokine ligand 17 (CCL17) and beta-chemokine receptor
6 (CCR6). Multiplex ELISA array and cDNA microarray analyses revealed that the DCPs shared some features of IL-4
and IL-15 DCs but displayed a pronounced proinflammatory phenotype. DCP-derived DCs showed antigen-uptake
and immune activation functions analogous to that of the peripheral blood-derived DCs. Furthermore, bone mar-
row HPC-derived DCP vaccines of tumor-bearing mice suppressed tumor growth in vivo.
This novel approach of generating DCP-DCs, which are different from known IL-4 and IL-15 DCs, overcomes both
quantitative and qualitative limitations in obtaining functional autologous DCs from a small number of HPCs with
great translational potential.
Background
Dendritic cells (DCs) initiate primary and memory
immune responses as well as activate innate immunity
and therefore, play a pivotal role in immunotherapy [1].
Accounting for only 0.02-0.2% of the total white blood
cells, the number of DCs that can be isolated from per-
ipheral blood is limited [2]. When cultured with supple-
ment of GM-CSF and IL-4, PBMCs or CD14-selected
monocytes generate DCs at about 50% of the starting
cell number. Furthermore, patients with cancer or
chronic infections often suffer from a compromised
immune system with increased myeloid suppressor cells
and dysfunctional DCs [3-9].
The developmental origin and tissue distribution of
various lineages of human versus mouse DCs are still
not well defined [10-15]. Transgenic mouse studies have
reported several transcription factors implicated in regu-
lating DC differentiation, which include zinc finger pro-
tein Ikaros, PU.1, relB, the helix-loop-helix (HLH)
transcription factor inhibitor of DNA binding or differ-
entiation 2 (Id2), interferon regulatory factor (IRF) 4
and 8, the Ets-domain transcription factor Spi-B, and
the Notch family of proteins [14,16]. In addition, growth
f a c t o r ss u c ha sF l t 3 L ,K L ,T P O ,T N F a,G M - C S F ,I L - 3 ,
IL-4, and IL-6 have been shown to promote develop-
ment and maturation of DCs [17-20]. * Correspondence: lchang@mgm.ufl.edu
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strictly required for the generation of DC progenitors
from HPCs in culture [21]. Int h el a b o r a t o r y ,G M - C S F
and IL-4 are routinely used to generate DCs from
adherent PBMCs, and GM-CSF and TNF-a can induce
differentiation of HPCs into interstitial DCs and Langer-
han’s cells in 12-14 days [22]. GM-CSF and IL-15, on
the other hand, drive DC differentiation from monocytes
and bone marrow (BM) but the role of IL-15 in myeloid
lineage development remains poorly understood [23,24].
IL-15 is a member of the gC receptor family of cyto-
kines which is expressed by a variety of cell types
important to the survival of fibroblasts, T cells and nat-
ural killer cells. IL-15 has been shown to promote the
survival of mature DCs through an autocrine antiapop-
totic mechanism [25,26], and IL-15-derived DCs are
reported to display Langerhans cell-like features with
strong T cell activation potential [23,24,27,28].
Although DCs can be derived from PBMCs, BM or
embryonic stem cells, the source and the amount of
these progenitor cells are restricted. While ex vivo DC
development and expansion approaches have been
attempted, only a moderate number of DCs can be gen-
erated with the most efficient system reporting about 94
fold expansion of DCs from BM cells [29,30]. The scar-
city and the variability of the various DC subsets have
significantly hindered fundamental studies of this impor-
tant lineage of immune cells. Innovative strategies that
can reproducibly generate a large amount of functional
DCs from a limited number of progenitor/stem cells are
urgently needed. Here we report a novel ex vivo culture
system that combines expansion of HPCs and differen-
tiation of a unique lineage of DC progenitors (DCPs).
This system supports expansion and development of
both human and mouse HPCs and DCs. The total num-
ber of DCs generated under this system reached more
than five orders of magnitude in 30-40 days, and the ex
vivo differentiated DCs displayed antigen capture, T cell
activation and tumor suppression functions similar to
that of the peripheral blood and BM-derived DCs. Thus,
a large number of autologous HPCs and DCs can now
be routinely generated from a small number of CD34
+
HPCs for the study of immune cell development with
potential of translational applications.
Methods
Cells and mice
CD34
+ cells used in this study were purified from BM,
mobilized peripheral blood (MPB) or cord blood (CB)
using magnetic beads (Miltenyi Biotec) following the
manufacturer’s instructions or purchased from AllCell
Inc. (San Mateo, CA), Cambrex (Baltimore, MD) and
National Disease Research Interchange (Philadelphia,
PA). Buffy coats of peripheral blood of healthy donors
were purchased from Civitan Blood Center (Gainesville,
FL). PBMCs were isolated from buffy coats of healthy
donors or from blood of cancer patients with approval
of the Institutional Review Board of University of Flor-
ida. B lymphoblastoid cell lines (BLCLs) were generated
by transforming peripheral blood B lymphocytes with
EBV as described previously [31]. The BLCLs were pro-
pagated in complete RPMI-1640 medium (Gibco, Grand
Island, NY) supplemented with 2 mM L-glutamine, 100
ug/ml streptomycin, 100 IU/ml penicillin and 10% heat
inactivated fetal bovine serum (FBS) at 37°C with 5%
CO2. The mouse fetal stromal cells were cultured in
Minimal Essential Medium Alpha (Gibco, Grand Island,
NY) supplemented with 2 mM L-glutamine, 100 ug/ml
streptomycin, 100 IU/ml penicillin and 20% heat inacti-
vated FBS (Gibco) at 37°C with 5% CO2.C T 2 6m o u s e
colon carcinoma cell line was purchased from ATCC
(catalogue no. CRL-2638) a n dc u l t u r e di nD u l b e c c o
Modified Eagle’s Medium (Gibco, Grand Island, NY)
supplemented with 2 mM L-glutamine, 100 ug/ml strep-
tomycin, 100 IU/ml penicillin and 10% heat inactivated
FBS (Gibco) at 37°C with 5% CO2.B A L B / cm i c ew e r e
obtained from Jackson Laboratory (Bar Harbor, ME)
with approval from the Institutional Animal Care and
Use Committee of University of Florida.
Antibodies and reagents
Fluorescein isothiocyanate (FITC)-conjugated Abs to
CD4, CD8, CD11c, CD33, CD34, CD38, CD86, IFN-g,
and HLA-DR, phycoerythrin (PE)-conjugated Abs to
CD4, CD8, CD11c, CD34, CD83, CD90, CD123, HLA-
DR, IFN-g,a n dT N F a, PerCP Cy5.5-conjugated Ab to
CD8, CD33, PE-Cy7-conjugated antibodies to CD8,
CD11b, CD11c, CD34, CD62L, CD40 and CD80, and
allophycocyanin (APC)-conjugated Abs to CD1a, CD3,
CD11c, CD14, CD33, CD69, CD83, CD90, CD133, IFN-
g and TNF-a were purchased from BD Pharmingen
(San Diego, CA), eBioscience (San Diego, CA), Miltenyi
Biotec (Auburn, CA), and Caltag Laboratories (Invitro-
gen, Carlsbad, CA) as listed in Additional file 1, Table
S1. Isotype-matched antibodies were included as con-
trols. HLA-A2 restricted, EBV BMLF1 GLC-peptide
(amino acid 280-288, GLCTLVAML) pentamer was pur-
chased from Proimmune (Springfield, VA).
Lentivector preparation and gene transfer
Lentivectors (LVs) were constructed as described pre-
viously [32-34]. The growth factor cDNAs were amplified
by PCR using primers designed to contain an optimized
translation initiation sequence (-CCACC-5’ to the initia-
tion codon). The primers used in this study are listed in
Additional file 2, Table S2. The amplified cDNAs were
cloned into the self-inactivating pTYF plasmid behind the
EF1a promoter. To generate feeder cells, mouse fetal
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infectious unit/cell in 12-well plates in a minimal volume
of 0.3 ml per well. After 2 h, 0.5 ml of fresh media was
added and cells were incubated at 37°C overnight. The
infected cells were continuously propagated for more than
50 passages and stable lentiviral transgene expression was
confirmed. The mouse CT26 tumor cells and DCs were
transduced with LVs encoding a codon-optimized human
HPV E6-E7 fusion protein and the chaperone protein cal-
nexin as previously described [35].
RNA extraction, RT-PCR and microarray analysis
RNA was extracted using Tri-reagent (MRC Inc., Cincin-
nati, OH) and oligo(dT)15-primed cDNA was made with
MMLV reverse transcriptase (Promega Inc., Madison,
WI). For semi-quantitative PCR, all reactions used the
same serially diluted cDNA normalized to the mouse
GAPDH (mGAPDH). The PCR amplification conditions
were as follows: denaturing temperature, 95°C; annealing
temperature, 55-62°C; extension temperature, 72°C; the
amplification cycles were 25-35 cycles. Products were
resolved by agarose gel electrophoresis and visualized by
ethidium bromide staining. The PCR primers used in this
study are listed in Additional file 2, Table S2.
For gene expression microarray analysis, RNA samples
were harvested from purified CD34
+HPCs, ex vivo cul-
tured DCPs, and adherent PBMC-derived IL-4 and IL-
15 DCs. These RNA samples were analyzed using Illu-
mina Human RefSeq-8 Expression BeadChips. RNA
quantity was determined with the Agilent RNA 6000
Nano Kit and Bioanalyzer. All samples displayed 28 S
and 5.8 S peaks indicating intact full length RNA. Synth-
esis of double-stranded cDNA and in vitro transcription
were performed with the Ambion Illumina TotalPrep kit
a c c o r d i n gt om a n u f a c t u r e r s ’ instructions. For each sam-
ple, input quantity for the first strand synthesis was nor-
malized to 200 ng. After in vitro transcription reaction,
yield of purified cRNA was assessed with the RiboGreen
assay and quality was assessed with the Agilent Bioana-
lyzer. BeadChip hybridization, staining and scanning
were performed according to Illumina whole genome
expression for BeadStation. For each sample, input of
cRNA was normalized to 1500 ng. As control, Strata-
gene Universal Human Reference (SUHR) RNA was
labeled with the Ambion TotalPrep kit. The labeled
cRNA was used as interchip hybridization replicates and
showed strong correlation. Biological replicate pairs
were analyzed and for unnormalized data, the linear r
2
was greater than 0.94 for all replicates.
Generation of mature DCs and antigen-specific immune
cells
PBMCs were isolated after Ficoll-Hypaque density cen-
trifugation (Sigma Aldrich, St Louis, MO). After plastic
adherence, the adherent cells were cultured in 50 ng/ml
GM-CSF and 25 ng/ml IL-4 (eBiosource International,
Inc. Camarillo, CA) in serum-free AIM-V medium
(Invitrogen, San Diego, CA) to generate immature DCs.
Immature DCs were transduced with LVs, and treated
with LPS (1 ug/ml) and TNFa ( 2 0u / m l )f o r2 4h rt o
induce maturation. The mature DCs were loaded with 5
ug/ml of specific peptides. The non-adherent PBMCs
were cocultured with irradiated (10 Gy) mature DCs, at
a 20:1 ratio, in AIM-V supplemented with IL-2 (12.5 U/
ml) and IL-7 (10 ng/ml) in 24-well plates. At day 12 of
coculture, the T cells were restimulated or harvested
for analysis as previously described [36,37]. The DCs
of BALB/c mice were generated from BM of tumor-
bearing mice and transduced with LVs as previously
described [38].
Quantitative cytokine and chemokine multiplexed
enzyme-linked immunosorbent assay (ELISA) arrays
DCs were washed twice with PBS and cultured in AIM-
V without growth factors and other supplements at a
density of 10
6 cells/ml for 24 hr. The supernatants were
collected and delivered to Quansys Biosciences (Logan,
UT) for custom multiplexed sample testing as previously
described [35]. Each sample was tested in triplicate. The
list of cytokines and chemokines tested included: IL-1a,
IL-1b, IL-2, IL-4, IL-5, IL-6, I L - 8 ,I L - 1 0 ,I L - 1 2 p 7 0 ,I L -
13, IL-17, IL-23, IFN-g,T N F - a,T N F - b,E o t o x i n ,
growth-related oncogene-alpha (GRO-a), monocyte che-
motactic protein 1 (MCP-1), MCP-2, regulated upon
activation, normal T-cell expressed and secreted cyto-
kine (RANTES), I-309 and thymus and activation-regu-
lated chemokine (TARC).
Antibody and pentamer staining and flow cytometry
For antibody (Ab) staining, single-cells were suspended
in PBS containing 2% FBS and 0.05% sodium azide and
pre-incubated with anti-CD16/CD32 Ab for 10 min to
block FcRs. Expression of cell surface markers was ana-
lyzed by standard four-color staining using FITC-, PE-,
PE-Cy7 or PerCP and APC-conjugated primary Abs. To
evaluate the expression of intracellular molecules, cells
were washed and restimulated for 5 hr in the presence
of brefeldin A (1 ug/ml) during the last 2.5 hr of cul-
ture. The stimulated cells were stained with anti-surface
marker Abs, washed and permeabilized with the Cyto-
Fix-Cytoperm kit (BD Pharmingen), according to the
manufacturer’s instruction, then stained with anti-intra-
cellular marker Abs, and analyzed by flow cytometry.
For multimer staining, the resting T cells were stained
with PE-labelled pentamer (Proimmune) for 12 min at
room temperature, followed by FITC-labeled or PE Cy7-
labelled anti-CD8 antibody for 30 min on ice and ana-
lyzed by flow cytometry. Data acquisition and analysis
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Quest and FACSDiva software, respectively (BD Bios-
ciences, San Jose, CA), or Flowjo software (Tree Star,
Inc. Ashland, OR).
Analysis of antigen uptake
Immature DCs were harvested and washed with AIM-V
twice and re-suspended in AIM-V at a concentration of
5x10
5 cells per ml. DCs were incubated with Dextran-
FITC or OVA-FITC (Molecular Probes, Inc., Eugene,
OR) at 37°C for 1 h; a parallel control was incubated at
4°C for 1 h. Cells were washed three times with cold
FACS buffer, resuspended in 100 ul of cold FACS buf-
fer, stained with APC-conjugated anti-CD11c Ab (BD
Biosciences, CA) and analyzed by flow cytometry.
In vivo DC vaccine tumor model
BALB/c CT26 colon cancer cells were transduced with
LV-optE6E7 encoding a fusion protein of HPV16 E6/E7
to generate the CT26-E6E7 cell line. The BALB/c mice
were inoculated with 1x10
5 CT26-E6E7 tumor cells sub-
cutaneously. Seven days later the mice were vaccinated
with 2-5 x10
5 immature DC/LV-optE6E7 or DC/LV-
optE6E7/LV-calnexin derived from tumor-bearing mice,
weekly for 2 weeks (n = 5 per group). Tumor size was
measured over time using calipers and mean tumor
volume (in mm
3) was determined.
Statistical analysis
The statistical analysis was performed using Student’st -
test and GRAPHPAD PRISM 4 software.
Results
Expansion of CD34
+ HPCs and development of DC
progenitors (DCPs)
HPCs can expand in culture but have limited potential
of maintaining hematopoietic stem cell phenotype and
function [39]. We established a series of lentivector-
modified stromal cell (LSC) lines to provide cell-free
and cell-associated signals that can support continuous
expansion of HPCs and differentiation of DCs (Fig. 1).
The LSC lines include LSC-KFT (KL, Flt3L, TPO), LSC-
KFTb (KL, Flt3L, TPO and bFGF), LSC-KFT63 (KL,
Flt3L, TPO, IL-6, and IL-3) and LSC-KFT63b (KT,
Flt3L, TPO, bFGF, IL-6, IL-3 and bFGF) for the expan-
sion of HPCs, and LSC-KFT-GM15 (KL, Flt3L, TPO,
GM-CSF and IL-15) and LSC-KFT-mGM15 (KL, Flt3L,
TPO, moues GM-CSF, and IL-15) for the differentiation
and expansion of human and mouse DCs, respectively.
LSC-KFT, LSC-KFTb, LSC-KFT63 and LSC-KFT63b
supported HPC expansion to similar extents, and the
total expansion fold varied with individual donors.
Under this culture condition, HPCs consistently
expanded twenty to one hundred-fold in twenty days,
followed by more than one thousand-fold expansion and
differentiation into DCPs in thirty days (Fig. 1A). This
dual culture system supports expansion and develop-
ment of DCs from both human and mouse HPCs.
To verify expression of the various growth factors in
LSCs, RNAs harvested from LSCs were analyzed by
semi-quantitative RT-PCR (Figure 1B and 1C). We con-
firmed that lentivector expression was stable even after
50 passages in these cell lines (data not shown). Highly
enriched human CD34
+ HPCs derived from adult mobi-
lized peripheral blood and BM expressed high level of
hematopoietic progenitor marker CD133 and low level
of CD33 (Figure 2A). This culture system supported
HPC expansion for both healthy donors and cancer
patients; for example, adult peripheral blood (PB) HPCs
expanded in LSC-KFT63b to about one hundred-fold in
two to three weeks (Figure 2A). Surface phenotype ana-
lysis indicated that the ex vivo expanded HPCs gradually
lost progenitor markers (CD34, CD90, and CD133),
which was accompanied by increased expression of mye-
loid differentiation markers CD38 and CD33 (Figure
2B). Similar results have been obtained with mouse BM
Sca1
+Lin
- (lineage-minus) HPCs (data not shown).
Differentiation and expansion of DCPs toward meyloid
DC-like phenotype
To see if the LSC culture system can generate functional
DCs, we first expanded CD34
+ HPCs in LSC-KFT63b.
After an initial 20-40-fold expansion, the cells were
transferred to LSC-KFT-GM15. The DCPs continued to
expand several orders of magnitude in 30 days; they
were then transferred to feeder-free culture supplemen-
ted with GM-CSF and IL-15 to generate functional
immature DCs as illustrated in Figure 3A.
Analysis of myeloid and DC lineage differentiation
markers including PU.1, Langerin, Id2, hIL7R-a, CCL17,
hCCR6, and E-cadherin (E-CAD) of the DCPs from day
0, 4, 9, 13, 23 and 39 by semi-quantitative RT-PCR
revealed a gradual increase in myeloid (PU.1) and DC
differentiation markers (Id2, hIL7R-a, CCL17, and
hCCR6), and a stochastic expression of differentiating
Langerhans cell markers (Langerin or CD207 and E-
CAD) as compared with monocyte-derived immature
DCs (imDC, Figure 3B). After 35 days, the DCPs dis-
played a differentiation profile similar to that of mono-
cyte-derived imDCs, except for E-CAD, which was
down-regulated. Kinetic analysis of monocyte and DC
markers including CD14, CD11c, CD1a, CD11b, HLA-
DR, CD83, CD40, CD123, and CD86 by flow cytometry
showed that the ex vivo-expanded DCPs gradually differ-
entiated toward mature DCs with increased expression
kinetics of costimulatory molecules CD40, CD86, and
DC maturation marker CD83 (Figure 3C). A representa-
tive flow cytometry analysis of DC markers of day 39
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displayed increased activation and maturation markers
resembling conventional mature DCs. Similar results
were observed with mouse DCPs expanded in the LSC-
KFT-mGM15 culture (not shown).
We next examined the gene expression profile of the
DCPs at different time points after differentiation from
HPCs using Illumina BeadChip Human RefSeq-8 arrays.
RNA samples were harvested from an early time point
(day 4) and a late time point (day 23), and compared to
RNAs harvested from CD34
+ HPCs and adherent
PBMC-derived IL-4 and IL-15 DCs. Cluster analysis of
unnormalized sample data showed that all biological
replicates (two DCPs, two IL-4 DCs and three CD34
+
HPCs) sorted into the same groups (Figure 4). Sample
dendogram revealed that the day 4 differentiated DCPs
displayed gene expression profile resembled CD34
+HPCs, whereas the day 23 differentiated DCPs dis-
played expression profile resembled IL-4 DCs (Figure 4).
Cytokine and chemokine secretion profiles of the ex vivo
generated DCs
As the morphology and surface marker expression pat-
tern of the HPC-DCPs resembled myeloid DCs, we
further examined the expression profile of inflammatory
cytokines and chemokines. For comparison, we included
the conventional IL-4 DCs and IL-15 DCs generated
from adherent PBMCs. HPC-DCPs from adult BM
CD34
+ HPCs were kept in feeder-free culture supple-
mented with GM-CSF and IL-15 to generate immature
DCs and then were treated with TNF-a and LPS to
induce maturation, and after extensive washes, the cells
were incubated in serum-free AIM-V medium at a den-
sity of 1x10
6 cells per ml for 24 hr. The supernatants
Figure 1 Ex vivo HPC to DC expansion and development system. (A) Schematic representation of the LSC culture system and the lentivector
constructs. The two LSC lines, LSC-KFT63b and LSC-KFT-GM15, produce the specified hematopoietic growth factors, which support the expansion
of HPCs and DCPs. (B) and (C) Semi-quantitative RT-PCR analyses of lentiviral transgene expression in the LSC lines. All of the growth factor
genes are human origin except for the mouse GM-CSF (mGM-CSF); the control endogenous mouse GAPDH (mGAPDH) gene expression is
shown at bottom.
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array, which simultaneously measures a panel of 23
cytokines and chemokines [35]. The results from two
donors are summarized in Table 1. We noted that
HPC-DCPs displayed a trend of upregulation of inflam-
matory cytokines and chemokines, with marked increase
in IL-1b, IL-6, GRO-a (CXCL1), I-309 (CCL1), MCP-1
(CCL2), and MCP-2 (CCL8) compared with the tradi-
tional IL-4 DCs, suggesting that the DCPs have potent
proinflammatory leukocyte chemotactic and activating
functions. The overall cytokine and chemokine profile of
DCP-derived DCs mimicked those of the IL-15 DCs
except that the DCP-derived DCs produced reduced
levels of IFN-g and TNFa, at levels similar to those of
the IL-4 DCs, yet with substantially increased expression
of GRO-a and MCP-1.
Antigen capture and T cell activation functions of the ex
vivo generated DCs
Professional antigen presenting cells can uptake and
process antigens and stimulate T cells. To examine
these functions, we compared the ex vivo generated DCs
with immature adherent PBMC-derived DCs (PBMC-
DCs) for their antigen uptake function by feeding them
with fluorescent DQ-OVA (OVA-FITC) and dextran-
FITC particles. The PBMC-DCs captured fluorescent
p a r t i c l e sa t3 7 ° Cb u tn o ta t4 ° C ,a sd e m o n s t r a t e dw i t h
flow cytometry. The day 37 DCP-DCs, which contained
a large number of CD11c-positive cells, captured anti-
gens as efficiently as did the PBMC-DCs (Figure 5A).
To see if the DCP-derived DCs were capable of activat-
ing antigen-specific T cells, we set up a DC/T cell cocul-
ture system as previously described [31,35,37]. The DCs
were transduced with LVs encoding a viral antigen, EBV
BMLF (LV-BMLF), or a truncated self-antigen tNGFR
(LV-tNGFR). After maturation, the DCs were cocultured
with autologous monocyte-depleted PBMCs for 12 days
to generate antigen-specific T cells. The activated T cells
were restimulated with the corresponding DCs and incu-
bated with a BMLF peptide-specific (GLCTLVAML,
HLA-A2*-restricted) MHC pentamer to detect antigen-
specific response. Both the DCP-DCs and the PBMC-
DCs induced antigen-specific T cell response when trans-
duced with LV-BMLF, but not LV-tNGFR (Figure 5B, left
panel). Intracellular staining for IFN-g expression in CD4
and CD8 T cells confirmed that the DCP-DCs activated
BMLF-specific T cells as effectively as did the PBMC-
DCs (Figure 5B, right panel). In contrast, the self-antigen
tNGFR did not register a substantial response.
In vivo tumor suppression mediated by DCP-DCs derived
from tumor-bearing mice
The above assays demonstrated that the HPC-derived
DCs displayed antigen presentation and T cell activation
functions similar to that of monocyte-derived DCs. To
examine their therapeutic potential, we designed an
experiment using a previously established syngeneic
mouse tumor model. BALB/c mice implanted with
CT26 colon cancer cells expressing a codon-optimized
Human Papilloma Virus 16 (HPV 16) E6 and E7 fusion
Figure 2 Expansion of CD34+ HPCs and phenotype analysis. (A) Ex vivo expansion kinetics of CD34+ HPCs in LSC culture. HPCs were
purified using anti-CD34 Ab magnetic beads and the expansion kinetics on LSC-KFT63b of HPCs from four donors are plotted at bottom. The
purified CD34+ cells were analyzed with anti-CD34, anti-CD133, and anti-CD33 Abs by flow cytometry and representative flow graphs of
mobilized PB CD34+ HPCs from three donors are illustrated. (B) Flow cytometry analysis of hematopoietic progenitor and differentiation markers
after HPC expansion in LSC culture for 9 days. The CD34+ HPCs of cord blood and adult PB were analyzed and presented.
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with DCs transduced with LVs encoding optE6E7 and
calnexin, a chaperone protein [31,35]. To mimic situa-
tion in a cancer patient, we derived DCPs from BM of
tumor-bearing mice to see if a protective anti-cancer
immune response can be induced. Figure 6A illustrates
the strategy of generating DCPs from BM of tumor-
bearing mice. CT26/optE6E7 tumors were first estab-
lished in BALB/c mice, after confirming tumor growth,
Sca1
+Lin
- HPCs were purified from BM of the tumor-
bearing mice. The HPCs were expanded in the LSC cul-
ture system as described; a representative mouse DCP
expansion curve is illustrated (Figure 6A). The mouse
DCPs expanded more than 6 orders of magnitude
within 30 days. To generate DC vaccines, the tumor
mouse-derived DCPs were differentiated for two days in
IL-15 DC medium as described in Materials and Meth-
ods and transduced with LV-optE6E7 or LV-optE6E7
plus LV-calnexin. BALB/c mice bearing CT26/optE6E7
tumors were divided into two groups of five mice each
group, and received two DC vaccinations at a one-week
interval. We observed that mice injected with DCs mod-
ified by LV-optE6E7 plus LV-calnexin displayed
increased survival than those modified by LV-optE6E7
alone (Figure 6B), a result consistent with previous find-
ings using BM-derived IL-4 DCs [35].
Discussion
The access to good quality and sufficient amount of func-
tional DCs is critical to the success of immunotherapy
Figure 3 Ex vivo generation of functional DCs. (A) Schematic illustration of expansion of human and mouse DCPs in culture. The human
(CD34
+) or mouse (Sca1
+/Lin
-) HPCs were cultured on LSC-KFT63b for 10 days, and then transferred to LSC-KFT-GM15 (LSC-KFT-mGM15 for
mouse cells) to expand for 30 days. The resulting DCPs were further cultured in medium supplemented with GM-CSF, IL-15 and growth factors
to induce immature and mature DCs. The average fold of expansion in each stage is indicated. (B) Kinetic analysis of myeloid cell differentiation
markers. The expression kinetics of molecular markers for myeloid cells including PU.1, Langerin, Id2, hIL7R-a, CCL17, hCCR6, and E-cadherin (E-
CAD) in the developing human DCPs were examined by RT-PCR. (C) Expression kinetics of DC surface markers of the DCPs based on flow
cytometry analysis. (D) Surface phenotype of day 37 DCPs from the LSC-KFT-GM15 culture. The number inside each of the flow graph represents
percentage of positive cells.
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able to generate a large number of DCs capable of acti-
vating antigen-specific effector T cells but not T
regulatory cells (Tregs). For examples, infusion of mye-
loid DCs and systemic administration of IL-2 have been
shown to induce and expand CD4
+FoxP3
+ Tregs in mye-
loma and renal cancer patients [31,40-42]. Here we pre-
sent a reliable and highly reproducible strategy based on
expansion of CD34
+ HPCs as well as differentiation of a
unique lineage of functional DC progenitors (DCPs)
using stromal cells engineered with lentivectors encoding
multiple growth factors. The ex vivo generated DCs
exhibited canonical antigen presentation functions
including antigen uptake, processing and activation of T
cells and in vivo anti-cancer effects.
The CD34
+ HPCs constitute a heterogeneous cell
population that can generate various lineages of DCs
[10,15,19,43,44]. We adopted a culture condition which
supports expansion of CD34
+ HPCs and DC differentia-
tion through the combination of cell-free and cell-asso-
ciated signals including those supporting hematopoietic
stem cell proliferation (KL, FL, TPO, IL-3, IL-6, bFGF),
myeloid DC differentiation (GM-CSF), as well as IL-15
which is known to promote leukocyte survival and
expansion. This unique ex vivo culture condition sup-
ports expansion of a novel lineage of DCs that are dif-
ferent from the conventional myeloid DCs. It is
plausible that the continued renewal of differentiating
DCPs in such a system was due to the lack of IL-4 and
TNF-a, the two common growth factors used in many
reported methods and known to induce DC maturation
Figure 4 Microarray dendogram analysis of ex vivo
differentiated DCPs. Gene expression profiles of CD34
+ HPC-
derived DCPs at early (day 4) and late (day 23) time points after
differentiation in LSC-KFT-GM15 were examined using Illumina
human whole-genome RefSeq 8 expression BeadChip containing
24,000 genes. The related cell types are grouped in clusters in the
dendogram, including day 4 and day 23 DCP, IL-4 DC (a single
donor and a mix of five donors), IL-15 DC and three CD34+ HPC
specimens. Stratagene Universal Human Reference RNA (SUHRR)
was included for quality control.
Table 1 Analysis of cytokines and chemokines secreted by mature DCs
Cytokines/Chemokines IL-4 DCs (pg/ml) IL-15 DCs (pg/ml) DCPs (pg/ml)
IL-1a 135 (32) 332 (1,228) ↑ 1,202 (239) ↑
IL-1b 338 (92) 601 (2,696) ↑ 8,582 (2,440) ↑↑
IL-2 6 (5) 7 (7) 6 (4)
IL-4 3 (3) 2 (4) 2 (1) ↓
IL-5 2 (1) 4 (7) ↑ 9 (6) ↑
IL-6 652 (53) 1,664 (8,036) ↑ 43,607 (4,605) ↑↑
IL-8 154,440 (55,237) 155,499 (297,615) ↑ 303,222 (286,234) ↑
IL-10 68 (53) 7 (114) 110 (162) ↑
IL-12p70 6 (3) 16 (25) ↑ 8 (6) ↑
IL-13 6 (5) 170 (148) ↑↑ 10 (11) ↑
IL-15 25 (23) 2,359 (248) ↑↑ 87 (81) ↑
IL-17 8 (4) 12 (13) ↑ 5 (6)
IL-23 17 (30) 79 (90) ↑ 215 (36) ↑
IFN-g < 1 ( < 1) 2,331 (1,905) ↑↑ < 1 (1)
TNFa 149 (72) 1,439 (3,152) ↑↑ 226 (70)
TNFb < 1 (2) 87 (67) ↑ 3 (6) ↑
Eotaxin 2 (3) 3 (3) 4 (2)
GRO-a 8,394 (2,158) 2,142 (15,744) 131,310 (19,241) ↑↑
I-309 1,989 (533) 15,086 (28,758) ↑ 18,141 (42,805) ↑↑
MCP-1 342 (571) 547 (4,971) ↑ 184,457 (127,001) ↑↑
MCP-2 11 (9) 339 (2,512) ↑↑ 2,381 (46) ↑
RANTES 1,588 (179) 2,552 (1,875) ↑ 1,666 (3,085) ↑
TARC 469,352 (337,109) 1,783 (1,636) ↓ 20,739 (14,855) ↓
Results are averages of triplicate analyses of cytokines and chemokines (pg/ml/10
6 cells/24 hr) secreted by mature DCs of two donors (the 2
nd donor shown in
parenthesis) using multiplex ELISA arrays. Up-(↑) and down-regulations (↓) are depicted by arrows, and double arrows indicate a difference more than ten-fold
from the IL-4 DCs.
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[ 3 0 ] .T h i sn o v e ll i n e a g eo fD C si sd i f f e r e n tf r o mt h e
commonly known IL-4 DCs or IL-15 DCs. Multiplex
cytokine and chemokine array analysis suggests that
DCPs resemble IL-15 DCs except that DCPs expressed
less TNFa and IFN-g, but much higher levels of
inflammatory cytokines (IL-1a, IL-1b, and IL-6) asso-
ciated with high levels of chemotactic factors (GRO-a
a n dM C P - 1 )a sc o m p a r e dw i t hI L - 1 5D C s( T a b l e1 ) .
The beadchip microarray analysis of gene expression
profile indicates that the ex vivo differentiated DCPs
share a common DC progenitor but branched in
Figure 5 Functional analyses of the ex vivo expanded DCPs. (A) Analysis of antigen capture function of the ex vivo derived DCPs. Antigen
capture was demonstrated using dextran-FITC or OVA-FITC particle internalization followed by flow cytometry analysis. Examples of FITC-positive
control PBMC-derived DCs are shown at top; antigen capture was detected at 37°C but not at 4°C. (B) Analysis of antigen-specific T cell
stimulation function. DCs were transduced with LVs encoding a control truncated NGFR (tNGFR) protein or BMLF protein of EBV, and incubated
with autologous T cells (from the same HLA-A*0201 donor) for 10-12 days. The BMLF-specific A*0201 TCR bearing T cells were detected using a
PE-conjugated MHC-peptide pentamer by flow cytometry (left panel). Antigen-specific effector function was analyzed based on intracellular
expression of IFN-g as described in Materials and Methods.
Figure 6 DCPs derived from BM HPCs of tumor-bearing mice suppress tumor growth in vivo. (A) Ex vivo expansion of DCPs from BM
HPCs of tumor-bearing Bulb/c mice. Balb/c mice were injected with CT26/optE6E7 tumor cells, and after 14 days, BM HPCs (Sca1
+/Lin
-) were
harvested and cultured on LSC-KFT cells. After ten days, the expanded HPCs were transferred to LSC-KFT-mGM15 to generate DCPs. A
representative mouse DCP expansion growth curve is shown. (B) Suppression of tumor growth in Balb/c mice immunized with LV-modified
DCPs. CT27/optE6E7 tumor cells were first established in Balb/c mice. The mice were immunized with the ex vivo expanded DCPs, which were
derived from the BM HPCs of CT26/optE67 tumor-bearing Balb/c mice. Two types of LV-modified DCs were tested: DCs transduced either by LV-
optE6E7 alone or by LV-optE6E7 plus LV-calnexin. The percentages of survival of the two groups of mice are illustrated. Survival was based on
tumor size smaller than 1 cm
3 without lesions.
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Page 9 of 12between the peripheral blood adherent cell-derived IL-4
DCs and IL-15 DCs (Fig. 4). Functional analysis shows
that DCP-DCs are fully capable of antigen presentation
and stimulation of antigen-specific T cells. We conclude
that the ex vivo derived DCP-DCs represent a unique
lineage of DCs displaying phenotype and function
between IL-4 DCs that have prominent adaptive
immune functions, and IL-15 DCs that have prominent
innate immune functions (manuscript in preparation).
Further developmental study may elucidate the in vivo
identity of the HPC-derived DCPs.
Several studies have reported that in addition to KL, FL
and TPO, other growth factors including bFGF, bone mor-
phogenetic protein 4 (BMP4), IL-3, IL-6 or stromal cell
derived factor-1 (SDF-1 or CXCL12) can help increase
CD34
+ HPC expansion and maintain their undifferentiated
state [45-47]. Epigenetic modification using DNA methyl-
transferase (DNMT) inhibitor 5-azacytidine (5-aza) and/or
histone acetylase inhibitor trichostatin A (TSA) can block
differentiation of hematopoietic stem cells and moderately
promote their expansion [48]. Supplementation of these
factors in the LSC system, however, does not further
increase HPC expansion potential (data not shown).
Nevertheless, this ex vivo system offers a convenient and
reproducible two-dimensional culture system for the study
of self-renewal and development of human HSC and DC.
Analysis of additional regulatory factors can be easily inte-
grated into this culture system.
The development and maturation of DCs in cancer
patients may be functionally defective, resulting in
reduced expression of class II MHC and diminished
antigen cross-priming activity [7,49-51]. In a previous
report, we have shown that IL-4 DCs from multiple
myeloma patients can be functionally improved through
upregulation of the chaperone protein calnexin, which
substantially increases the secretion of inflammatory
cytokines and chemokines accompanied by a strong
memory T cell response [31,35]; DCP-DCs, as illustrated
here, may accomplish the same without further modifi-
cations. As IL-15 has been shown to reduce Treg activ-
ities and increase antigen-specific CD8 T cell response
in vitro and in vivo,t h eex vivo generated DCP-DCs
have potential of overcoming DC dysfunctions in cancer
patients [26,52,53]. DCPs from cancer patients including
multiple myeloma, acute myeloid leukemia, acute lym-
phoblastic leukemia, Hodgkin’s lymphoma and glioblas-
toma patients have been successfully generated from a
small number of BM CD34
+ HPCs over several orders
of magnitude ( > 10
6) (unpublished). Thus, this ex vivo
approach avoids potential immune suppressive microen-
vironment of DC development in patients. Further
efforts in validated GMP process development and stan-
dardization of the feeder culture system are needed
before DCP-DCs are ready for clinical trials.
Conclusions
This ex vivo DC development system supports a robust
expansion of a novel DC lineage in culture from a small
number of CD34
+ HPCs, which provides a critical solu-
tion to problems often encountered in immunotherapy.
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